JP2008512445A - 炎症状態の治療のためのリポソーム性グルココルチコイドの使用 - Google Patents

炎症状態の治療のためのリポソーム性グルココルチコイドの使用 Download PDF

Info

Publication number
JP2008512445A
JP2008512445A JP2007530849A JP2007530849A JP2008512445A JP 2008512445 A JP2008512445 A JP 2008512445A JP 2007530849 A JP2007530849 A JP 2007530849A JP 2007530849 A JP2007530849 A JP 2007530849A JP 2008512445 A JP2008512445 A JP 2008512445A
Authority
JP
Japan
Prior art keywords
derivative
pharmaceutical composition
liposome
mps
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007530849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512445A5 (https=
Inventor
バレンホルズ、イエチェズケル
ナパルステク、ヤーコブ
アブニル、ユバル
ウルマンスキー、リナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of JP2008512445A publication Critical patent/JP2008512445A/ja
Publication of JP2008512445A5 publication Critical patent/JP2008512445A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007530849A 2004-09-09 2005-09-11 炎症状態の治療のためのリポソーム性グルココルチコイドの使用 Pending JP2008512445A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60814004P 2004-09-09 2004-09-09
PCT/IL2005/000962 WO2006027786A2 (en) 2004-09-09 2005-09-11 Use of liposomal glucocorticoids for treating inflammatory states

Publications (2)

Publication Number Publication Date
JP2008512445A true JP2008512445A (ja) 2008-04-24
JP2008512445A5 JP2008512445A5 (https=) 2008-10-30

Family

ID=35432741

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007530849A Pending JP2008512445A (ja) 2004-09-09 2005-09-11 炎症状態の治療のためのリポソーム性グルココルチコイドの使用
JP2007530850A Expired - Fee Related JP5355890B2 (ja) 2004-09-09 2005-09-11 グルココルチコイドおよびグルココルチコイド誘導体のリポソーム性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007530850A Expired - Fee Related JP5355890B2 (ja) 2004-09-09 2005-09-11 グルココルチコイドおよびグルココルチコイド誘導体のリポソーム性組成物

Country Status (7)

Country Link
US (3) US8932627B2 (https=)
EP (2) EP1793804A2 (https=)
JP (2) JP2008512445A (https=)
CN (2) CN101043875B (https=)
AU (2) AU2005281351B2 (https=)
CA (2) CA2579786A1 (https=)
WO (2) WO2006027787A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013147480A (ja) * 2012-01-23 2013-08-01 Cac:Kk 医薬組成物及びこれを用いた薬用化粧品
JP2025506762A (ja) * 2022-02-25 2025-03-13 中南大学湘雅医院 関節鎮痛用ナノ製剤およびその調製方法並びに用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
AU2004233873B2 (en) 2003-04-25 2010-11-18 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
WO2006027787A1 (en) * 2004-09-09 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
DE102007060198A1 (de) 2007-12-14 2009-06-18 Osram Gesellschaft mit beschränkter Haftung Konversions-LED
DE102007060199A1 (de) 2007-12-14 2009-06-18 Osram Gesellschaft mit beschränkter Haftung Leuchtstoff und Beleuchtungssystem mit derartigem Leuchtstoff
KR101975843B1 (ko) * 2008-05-23 2019-05-09 더 유니버시티 오브 브리티쉬 콜롬비아 리포좀 나노입자에 사용하기 위한 변형된 약물
EP2127639A1 (en) * 2008-05-26 2009-12-02 Universiteit Utrecht Holding B.V. Corticosteroid containing liposomes for treatment of cardiovascular diseases
CN101601652B (zh) * 2008-06-11 2012-07-04 天津金耀集团有限公司 糠酸莫米松脂质体乳膏
TR201908314T4 (tr) * 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
EP2531175A2 (en) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
JP2011246464A (ja) * 2010-04-28 2011-12-08 Wakamoto Pharmaceutical Co Ltd ジクロフェナクナトリウムを封入した後眼部到達用ポリマーコーティングリポソーム
CA2834968C (en) 2011-01-05 2018-01-09 Livon Laboratories Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
WO2013059922A1 (en) 2011-10-25 2013-05-02 The University Of British Columbia Limit size lipid nanoparticles and related methods
SI2854769T1 (sl) * 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
JP6151786B2 (ja) * 2013-09-30 2017-06-21 富士フイルム株式会社 医療支援装置、医療支援装置の制御方法、医療支援プログラム及び医療支援システム
US20150132369A1 (en) * 2013-11-09 2015-05-14 Exir Nano Sina Company Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof
CN103720658B (zh) * 2014-01-07 2015-10-07 中国药科大学 肝素修饰的阿霉素脂质体制剂及其制备方法
WO2017105344A1 (en) * 2015-12-17 2017-06-22 Nanyang Technological University Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them
TWI754659B (zh) * 2016-08-08 2022-02-11 台灣微脂體股份有限公司 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
TWI728255B (zh) 2017-07-24 2021-05-21 國邑藥品科技股份有限公司 包含弱酸藥物之脂質體組成物及其用途
ES2971091T3 (es) * 2017-08-30 2024-06-03 Bristol Myers Squibb Co Un método para supervisar las respuestas farmacodinámicas mediadas por la administración de glucocorticoides in vivo
IL278513B (en) 2018-05-07 2022-09-01 Pharmosa Biopharm Inc A pharmaceutical preparation for the controlled release of treprostinil
TWI755629B (zh) * 2018-09-13 2022-02-21 台灣微脂體股份有限公司 含鎮靜藥物之緩釋藥物組合物及其用途
AU2019339401B9 (en) * 2018-09-14 2022-11-03 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
KR102164260B1 (ko) * 2018-10-30 2020-10-12 (주)유에이치에이 메틸프레드니솔론 및 줄기세포를 유효성분으로 포함하는 다발성 경화증의 예방 또는 치료용 조성물
CN113827738B (zh) * 2020-06-08 2024-04-09 沈阳药科大学 唾液酸修饰地塞米松棕榈酸酯脂质体及其制备和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56161317A (en) * 1980-05-15 1981-12-11 Green Cross Corp:The Pharmaceutical preparation of fatty corpuscle of steroid
WO2003105805A1 (en) * 2002-06-12 2003-12-24 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
WO2004047792A2 (de) * 2002-11-24 2004-06-10 Novosom Ag Liposomale glucocorticoide

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757056A (en) * 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
WO1990006775A1 (en) 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5189018A (en) * 1991-08-19 1993-02-23 Wayne State University Method for reduction of central nervous system (cns) edema resulting from head and spinal cord trauma
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
WO1996032930A1 (en) * 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5817856A (en) * 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
DE19607722A1 (de) * 1996-02-29 1997-09-04 Freisleben H J Dr Tetraetherlipide und diese enthaltende Liposomen sowie deren Verwendung
ATE252372T1 (de) 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
JP2001503396A (ja) * 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US5948822A (en) * 1996-12-17 1999-09-07 Lidak Pharmaceuticals Treatment of hyperproliferative skin disorders with C18 to C26 alphatic alcohols
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030185826A1 (en) * 1999-02-24 2003-10-02 Tobinick Edward L. Cytokine antagonists for the treatment of localized disorders
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20030129222A1 (en) * 2000-11-21 2003-07-10 Gabriel Lopez-Berestein Liposomal imexon
DK1347743T3 (da) 2000-12-07 2006-07-03 Univ Utrecht Holding Bv Præparat til behandling af inflammatoriske lidelser
IL156976A0 (en) * 2001-02-13 2004-02-08 Yissum Res Dev Co Carotenoid-loaded liposomes
EP2664233B1 (en) 2001-07-11 2014-10-08 Max Co., Ltd. Gardening binder
AU2002334358B2 (en) 2001-09-06 2008-02-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposome formulations with a predefined release profile
US20040219201A1 (en) 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
AU2003259028A1 (en) * 2002-06-10 2003-12-22 Combinatorx, Incorporated Combinations for the treatment of rheumatoid arthritis
US20060093595A1 (en) * 2002-07-05 2006-05-04 Mahesh Jayachandra Methods, compositions and kits for treating damage to excitable tissue
EP1393720A1 (en) 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
WO2006027787A1 (en) * 2004-09-09 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
PL2308514T3 (pl) * 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56161317A (en) * 1980-05-15 1981-12-11 Green Cross Corp:The Pharmaceutical preparation of fatty corpuscle of steroid
WO2003105805A1 (en) * 2002-06-12 2003-12-24 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
WO2004047792A2 (de) * 2002-11-24 2004-06-10 Novosom Ag Liposomale glucocorticoide

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013147480A (ja) * 2012-01-23 2013-08-01 Cac:Kk 医薬組成物及びこれを用いた薬用化粧品
JP2025506762A (ja) * 2022-02-25 2025-03-13 中南大学湘雅医院 関節鎮痛用ナノ製剤およびその調製方法並びに用途

Also Published As

Publication number Publication date
AU2005281352A1 (en) 2006-03-16
WO2006027786A2 (en) 2006-03-16
US20150093434A1 (en) 2015-04-02
CN101048138B (zh) 2010-12-08
US20080003276A1 (en) 2008-01-03
EP1791525A1 (en) 2007-06-06
JP5355890B2 (ja) 2013-11-27
WO2006027786A8 (en) 2006-08-31
CN101043875B (zh) 2014-05-07
CA2579786A1 (en) 2006-03-16
CA2579695A1 (en) 2006-03-16
AU2005281352B2 (en) 2011-01-27
US20080058294A1 (en) 2008-03-06
WO2006027787A1 (en) 2006-03-16
WO2006027786A3 (en) 2006-04-27
EP1793804A2 (en) 2007-06-13
CN101043875A (zh) 2007-09-26
US7744920B2 (en) 2010-06-29
JP2008512446A (ja) 2008-04-24
CN101048138A (zh) 2007-10-03
AU2005281351A1 (en) 2006-03-16
US8932627B2 (en) 2015-01-13
AU2005281351B2 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
AU2005281351B2 (en) Use of liposomal glucocorticoids for treating inflammatory states
JP6609286B2 (ja) ヒトにおける炎症性障害の治療用リポソームコルチコステロイド
CN103118683B (zh) 重建高密度脂蛋白制剂及其生产方法
US20060008517A1 (en) Treatment of age-related memory impairment
US20200330432A1 (en) Therapeutics for preterm labor management
JP5199666B2 (ja) 白血病を治療するための組成物および方法
CN112702993A (zh) 适用于关节递送的药物组合物及其在治疗关节疼痛中的用途
WO2022187607A1 (en) Pharmaceutical compositions with reduced side effect and methods of using the same
JP2023123843A (ja) 弱酸性薬物の制御放出のための医薬組成物およびその使用
JP2021532074A (ja) 関節内ステロイドの合併症を軽減する方法
US20180360758A1 (en) Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them
WO2025096949A1 (en) Liposomal composition of intra-articular corticosteroid for pain control
HK40087158A (zh) 用於疼痛控制的关节内皮质类固醇的药物组合物
HK40041739A (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120703